Transparency and Pharmaceutical Practice from a MeTA Country

1,518 views

Published on

Presentation by Normita D. Leyesa, President, Philippine Pharmacists Association on Transparency and Pharmaceutical Practice from a MeTA Country during the 69th FIP Congress, Istanbul, September 2009.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,518
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
9
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transparency and Pharmaceutical Practice from a MeTA Country

  1. 1. FIP-WHO META Istanbul, Turkey September 5, 2009 1 Normita D. Leyesa, RPh, MS President, Philippine Pharmacists Association MeTA Council Member Transparency and PharmaceuticalTransparency and Pharmaceutical Practice from a MeTA Country:Practice from a MeTA Country: The MeTA Philippines Country ReportThe MeTA Philippines Country Report 1
  2. 2. FIP-WHO META Istanbul, Turkey September 5, 2009 2 Medicine Transparency AllianceMedicine Transparency Alliance (MeTA) initiative proposes to(MeTA) initiative proposes to improve accessimprove access to medicinesto medicines throughthrough transparencytransparency andand accountabilityaccountability..
  3. 3. FIP-WHO META Istanbul, Turkey September 5, 2009 33 The Philippines WorkThe Philippines Work Plan for the Phase IPlan for the Phase I 2009-20102009-2010 Objective:Objective: Provide adequate information that would strengthen decision-making and implementation of processes along the medicines registration, selection, procurement, and use.
  4. 4. FIP-WHO META Istanbul, Turkey September 5, 2009 4 Preparation ofPreparation of the Work Planthe Work Plan  Identification of priority areas for MeTAIdentification of priority areas for MeTA intervention by scoping visits, consultations, andintervention by scoping visits, consultations, and stakeholder mappingstakeholder mapping  Identification of areas supported by otherIdentification of areas supported by other international development partners andinternational development partners and stakeholdersstakeholders  Line-up of activities and allocated budget wereLine-up of activities and allocated budget were finally deliberated and approvedfinally deliberated and approved
  5. 5. FIP-WHO META Istanbul, Turkey September 5, 2009 5 Three Key Points ofThree Key Points of Phase IPhase I 1.1. Country structure and commitmentCountry structure and commitment 2.2. Transparency: disclosure, data collectionTransparency: disclosure, data collection and analysisand analysis 3.3. Accountability: multi-stakeholderAccountability: multi-stakeholder approach and good governanceapproach and good governance
  6. 6. FIP-WHO META Istanbul, Turkey September 5, 2009 6 2009-20102009-2010 Strategic Work PlanStrategic Work Plan  Developing Information on Prices, Availability,Developing Information on Prices, Availability, Financing Mechanisms and Rational Drug UseFinancing Mechanisms and Rational Drug Use  Generating Information to Improve Quality ofGenerating Information to Improve Quality of PharmaceuticalsPharmaceuticals  Setting up Systems for Transparency in MedicinesSetting up Systems for Transparency in Medicines Registration, Selection, Procurement and UsageRegistration, Selection, Procurement and Usage  Supporting Transparency Agenda in DecentralizedSupporting Transparency Agenda in Decentralized SystemsSystems  Preparation of Budget for the ActivitiesPreparation of Budget for the Activities
  7. 7. FIP-WHO META Istanbul, Turkey September 5, 2009 7 KEY OUTCOMESKEY OUTCOMES
  8. 8. FIP-WHO META Istanbul, Turkey September 5, 2009 8 Key Outcome 1:Key Outcome 1: Available information onAvailable information on medicines quality, registration,medicines quality, registration, access, promotions, and rationalaccess, promotions, and rational drug usedrug use  Analysis of existing pharmaceutical data (ongoing)Analysis of existing pharmaceutical data (ongoing)  Conduct of Level II and III Survey on medicinesConduct of Level II and III Survey on medicines (ongoing)(ongoing)  Assessment of Public SectorAssessment of Public Sector – Procurement (including PITC) of medicinesProcurement (including PITC) of medicines – Design ofDesign of ee-procurement system-procurement system – Assessment of the current systems for financingAssessment of the current systems for financing medicines for the poor (TOR)medicines for the poor (TOR)  Survey of quality of medicines using the “FDA in aSurvey of quality of medicines using the “FDA in a suitcase”suitcase”  Study on medicines promotion and advertisementStudy on medicines promotion and advertisement (TOR)(TOR)
  9. 9. FIP-WHO META Istanbul, Turkey September 5, 2009 9 Key Outcome 2:Key Outcome 2: Setting up of informationSetting up of information structures and systemsstructures and systems  Improvement of the medicines registrationImprovement of the medicines registration  FDA websiteFDA website  Philippine National Drug Formulary WebsitePhilippine National Drug Formulary Website  Support to the implementation of the ElectronicSupport to the implementation of the Electronic Essential Drug Price Monitoring System (E-EDPMS) atEssential Drug Price Monitoring System (E-EDPMS) at the regional and provincial levelsthe regional and provincial levels  Development of systems for monitoring andDevelopment of systems for monitoring and evaluation of ethical practices of industry and theevaluation of ethical practices of industry and the medical professionmedical profession  Development and testing of monitoring tools forDevelopment and testing of monitoring tools for prescription auditsprescription audits
  10. 10. FIP-WHO META Istanbul, Turkey September 5, 2009 10 Key Outcome 3:Key Outcome 3: Improvement of technicalImprovement of technical capacity for disclosure, analysis, andcapacity for disclosure, analysis, and the use of information and evidencethe use of information and evidence  Pharmaceutical Management and Good GovernancePharmaceutical Management and Good Governance Course for LGU Health Managers and Local ChiefCourse for LGU Health Managers and Local Chief ExecutivesExecutives  National Good Governance in Medicines AwardsNational Good Governance in Medicines Awards  Strengthening of Drug Therapeutic Committees (DTC) atStrengthening of Drug Therapeutic Committees (DTC) at Regional and Provincial levelsRegional and Provincial levels  Technical capacity building for DTCsTechnical capacity building for DTCs  Development of tools for monitoring/evaluation of DTCsDevelopment of tools for monitoring/evaluation of DTCs  Piloting of the Pharmaceutical Bench BookPiloting of the Pharmaceutical Bench Book
  11. 11. FIP-WHO META Istanbul, Turkey September 5, 2009 11 Key Outcome 4:Key Outcome 4: Setting up mechanism forSetting up mechanism for advocacy and participation inadvocacy and participation in decision making processesdecision making processes  MeTA Roundtable discussionsMeTA Roundtable discussions  PublicationsPublications – Development of the MeTA WebsiteDevelopment of the MeTA Website – Publication of Proceedings for MeTA ForumPublication of Proceedings for MeTA Forum – Publication of Baseline AssessmentsPublication of Baseline Assessments  Annual MeTA ForumAnnual MeTA Forum
  12. 12. FIP-WHO META Istanbul, Turkey September 5, 2009 12 Key Outcome 5:Key Outcome 5: Sustaining a Multi-stakeholderSustaining a Multi-stakeholder CollaborationCollaboration  MeTA Council and Secretariat OperationsMeTA Council and Secretariat Operations  Support to Civil Society OrganizationsSupport to Civil Society Organizations – Coalition for Health Advocacy and TransparencyCoalition for Health Advocacy and Transparency
  13. 13. FIP-WHO META Istanbul, Turkey September 5, 2009 13 ““The challenges in transparency andThe challenges in transparency and accountability on medicine registration,accountability on medicine registration, selection, procurement, and use in theselection, procurement, and use in the Philippines are enormous.Philippines are enormous. These can be summed up into two:These can be summed up into two: non-non- accessibility of dataaccessibility of data to policy, decisionto policy, decision makers, and consumers and themakers, and consumers and the lack oflack of tools and structurestools and structures for adequatefor adequate reporting, disclosure and feedback.”reporting, disclosure and feedback.”
  14. 14. FIP-WHO META Istanbul, Turkey September 5, 2009 14 With the assistance of MeTAWith the assistance of MeTA International, and the Department ofInternational, and the Department of International Development (DFID) UK,International Development (DFID) UK, and the support of the World Healthand the support of the World Health Organization, we will be able toOrganization, we will be able to surmount these challenges andsurmount these challenges and ultimately, improve the healthcareultimately, improve the healthcare delivery system in the Philippines fordelivery system in the Philippines for the benefit of the Filipino people.the benefit of the Filipino people.
  15. 15. FIP-WHO META Istanbul, Turkey September 5, 2009 15 Thank You!Thank You!

×